| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Jean-Christophe Marine | Q6169071 |
| P2093 | author name string | Aart G Jochemsen | |
| Michael A Dyer | |||
| P2860 | cites work | Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity | Q28270986 |
| P433 | issue | Pt 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 371-378 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Journal of Cell Science | Q1524177 |
| P1476 | title | MDMX: from bench to bedside | |
| P478 | volume | 120 |
| Q27661400 | A Left-Handed Solution to Peptide Inhibition of the p53-MDM2 Interaction |
| Q37687503 | A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility |
| Q39632042 | A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis |
| Q39472408 | A critical role for noncoding 5S rRNA in regulating Mdmx stability |
| Q91720089 | A single synonymous mutation determines the phosphorylation and stability of the nascent protein |
| Q39632109 | A stapled p53 helix overcomes HDMX-mediated suppression of p53. |
| Q37703117 | Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations |
| Q27681154 | An Ultrahigh Affinity d -Peptide Antagonist Of MDM2 |
| Q36609221 | Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties |
| Q27657769 | Apamin as a novel template for structure-based rational design of potent peptide activators of p53 |
| Q35950537 | Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation |
| Q99551088 | CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells |
| Q38797572 | Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner |
| Q36321693 | Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells. |
| Q36216371 | Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction. |
| Q35795880 | Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations |
| Q27653453 | Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes |
| Q27663612 | D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms |
| Q34368142 | Deconstructing nucleotide binding activity of the Mdm2 RING domain |
| Q35781290 | Designer macrocyclic organo-peptide hybrids inhibit the interaction between p53 and HDM2/X by accommodating a functional α-helix |
| Q30670705 | Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in |
| Q39348126 | Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. |
| Q90575977 | Dissenting degradation: Deubiquitinases in cell cycle and cancer |
| Q37085951 | Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer |
| Q37004455 | Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma |
| Q35199094 | Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor |
| Q29248201 | Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation |
| Q35916594 | Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells |
| Q37053063 | Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction |
| Q33635059 | Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system |
| Q34146539 | Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway. |
| Q27936404 | Gene activation by dissociation of an inhibitor from a transcriptional activation domain |
| Q33763680 | Genetic and Epigenetic Discoveries in Human Retinoblastoma |
| Q42232791 | Guarding the guardian: Mdmx plays important roles in setting p53 basal activity and determining biological responses in vivo |
| Q34133124 | HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea |
| Q35552029 | HIF-2α mediates hypoxia-induced LIF expression in human colorectal cancer cells |
| Q35123240 | Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability |
| Q33524716 | Identification and characterization of the first small molecule inhibitor of MDMX |
| Q39317432 | Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. |
| Q37379017 | Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases |
| Q37855826 | Inhibitors of MDM2 and MDMX: a structural perspective. |
| Q37480094 | Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. |
| Q35922756 | Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined |
| Q38938719 | Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine |
| Q36579823 | Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study |
| Q27660480 | Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry |
| Q29616507 | Linking the p53 tumour suppressor pathway to somatic cell reprogramming |
| Q36094618 | MDM2 and MDM4: p53 regulators as targets in anticancer therapy |
| Q44435579 | MDM2/MDMX inhibitor peptide: WO2008106507. |
| Q24337839 | MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway |
| Q24316349 | MDM4 binds ligands via a mechanism in which disordered regions become structured |
| Q37096987 | MDM4 is a key therapeutic target in cutaneous melanoma |
| Q85072453 | MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis |
| Q37099799 | Maternal embryonic leucine zipper kinase (MELK) reduces replication stress in glioblastoma cells |
| Q41287457 | Mdm2 and tumorigenesis: evolving theories and unsolved mysteries |
| Q37508606 | Mdm2-mediated ubiquitylation: p53 and beyond. |
| Q24336863 | MdmX is a substrate for the deubiquitinating enzyme USP2a |
| Q36483408 | MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice |
| Q42546083 | Mdmx promotes genomic instability independent of p53 and Mdm2. |
| Q38443362 | Modulation of alternative splicing by anticancer drugs |
| Q41455736 | Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo |
| Q36070574 | Mutant p53: one name, many proteins |
| Q33320072 | Mutation analysis of the MDM4 gene in German breast cancer patients |
| Q33514226 | N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. |
| Q39387810 | New Insights in Thyroid Cancer and p53 Family Proteins. |
| Q33775959 | Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions |
| Q28484086 | On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53 |
| Q38558085 | Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts |
| Q34287830 | P53 mdm2 inhibitors |
| Q40017147 | PML enhances the regulation of p53 by CK1 in response to DNA damage |
| Q52663744 | Peli1 modulates the subcellular localization and activity of Mdmx. |
| Q51895782 | Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX |
| Q33899450 | Posttranslational modification of p53: cooperative integrators of function |
| Q39612489 | Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells |
| Q52584348 | Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. |
| Q36581671 | Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. |
| Q28550543 | Probing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy Methods |
| Q41287206 | Protecting the genome from mdm2 and mdmx |
| Q36678014 | Protein phosphatase 1 inhibits p53 signaling by dephosphorylating and stabilizing Mdmx. |
| Q37631181 | ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. |
| Q37524156 | Recent advances in validating MDM2 as a cancer target. |
| Q96348276 | Regulating tumor suppressor genes: post-translational modifications |
| Q39812243 | Ribosomal protein S7 is both a regulator and a substrate of MDM2 |
| Q28079939 | Role of MDM2 and MDMX in DNA repair |
| Q49422353 | Role of the N-terminal lid in regulating the interaction of phosphorylated MDMX with p53. |
| Q84908928 | S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia |
| Q35411745 | Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach |
| Q29568203 | Self-association of the Gal4 inhibitor protein Gal80 is impaired by Gal3: evidence for a new mechanism in the GAL gene switch |
| Q27679680 | Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy |
| Q39492626 | Stochastic and Deterministic Models of Cellular p53 Regulation. |
| Q34575687 | Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. |
| Q27653993 | Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX |
| Q30316740 | Structure of full-length p53 tumor suppressor probed by chemical cross-linking and mass spectrometry |
| Q27322960 | Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation |
| Q27649717 | Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans |
| Q27660219 | Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions |
| Q52628104 | TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases. |
| Q37068706 | Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? |
| Q36293839 | Targeting Mdmx to treat breast cancers with wild-type p53. |
| Q38194418 | Targeting RNA polymerase I to treat MYC-driven cancer. |
| Q33915473 | Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. |
| Q38059739 | Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy |
| Q34030117 | The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor |
| Q47096280 | The Role of MDM2 in Promoting Genome Stability versus Instability. |
| Q37426771 | The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells |
| Q26744087 | The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy |
| Q51281633 | The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis. |
| Q35122947 | The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo |
| Q34020353 | The p53 orchestra: Mdm2 and Mdmx set the tone |
| Q37503463 | The p53-MDM2/MDMX axis - A chemotype perspective |
| Q33712095 | The role of MDM2 and MDM4 in breast cancer development and prevention. |
| Q37845797 | The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious |
| Q37762069 | The tumor suppressor p53: from structures to drug discovery |
| Q34915943 | Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching |
| Q37261088 | Turning a scorpion toxin into an antitumor miniprotein |
| Q38145508 | Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. |
| Q37748214 | Using mice to examine p53 functions in cancer, aging, and longevity |
| Q34209099 | Validation of MdmX as a therapeutic target for reactivating p53 in tumors |
| Q42058130 | Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo |
| Q39310656 | c-Abl phosphorylates Hdmx and regulates its interaction with p53. |
| Q34029735 | p53 at a glance |
| Q44950735 | p53 is activated in response to disruption of the pre-mRNA splicing machinery. |
| Q34300569 | p53 post-translational modification: deregulated in tumorigenesis |
| Q42362115 | p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance |
Search more.